CV
Univ. Prof. Dr. med. Jürgen Wolf
Academic education
1978 - 1984: Medical School, University of Freiburg
Scientific degrees
2003: Professor for Internal Medicine, University of Cologne
1998: Board certification Hematology / Medical Oncology, Ärztekammer Nordrhein
1997:Postdoctoral lecturing qualification (Habilitation), University of Cologne
1995: Board certification Internal Medicine, Ärztekammer Nordrhein
1986: MD and doctoral thesis, Medical Faculty, University of Freiburg
Scientific career
2012: Professorship for Interdisciplinary Translational Oncology University of Cologne
2010: Foundation of the Network Genomic Medicine Lung Cancer (www.ngm-cancer.com) together with Reinhard Büttner
2006: Medical Director of the Center for Integrated Oncology (CIO) University Hospital Köln
2005: Initiation of the Lung Cancer Program within the CIO together with Roman Thomas and foundation of the Lung Cancer Group Cologne (LCGC)
2004: Coordination of the establishment of the Center for Integrated Oncology (CIO) at the University Hospital Cologne
2000 - 2004: Co-chairman of the German Hodgkin´s Lymphoma Study Group
1996: Senior Consultant, Dep. I of Internal Medicine, Cologne
1990 - 1995: Associate in clinical research, Dept. I of Internal Medicine, University Hospital Cologne
1985 - 1990: Postdoctoral fellow, German Cancer Research Center Heidelberg, Tumorvirology Group (H.zur Hausen)
Honors/ Awards/ Memberships
2016: Innovation Award of the state of North Rhine-Westphalia for the foundation of the Network Genomic Medicine
Contact Information
Univ. Prof. Dr. med. Jürgen Wolf
Medical Director Center for Integrated Oncology CIO Köln
University Hospital of Cologne
Department I for Internal Medicine, Center for Integrated Oncology Köln Bonn (CIO)
10 most relevant publications
- Besse B, Lin JJ, Bazhenova L, Goto K, de Langen AJ, Kim DW, Wolf J, Springfeld C, Popat S, Lim DWT, Nagasaka M, Hong JY, Baik CS, Hervieu A, Moreno V, Yang N, Kollengode K, Yang H, Xu Y, Calvet CY, Yuan Y, Hammell AB, Drilon A, Solomon BJ. Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial. Nat Med. 2026;32(2):682-689. doi:10.1038/s41591-025-04079-7
- Till A, Siddiqui RA, Altbürger C, Schwarz R, Huebner T, Wolf J, Andres D, Anker A, Aretz S, Haack TB, Berlage T, Beule D, Boerries M, Buchhalter I, Bussmann J, Engel C, Friedrichs J, Fröhling S, Haenisch B, Hahne A, Hübschmann D, von Kessel F, Klatt R, Kreutzfeldt S, Kron A, Krude H, Lübbe A, Lührig U, Malek N, Mertes C, Möller Y, Mundlos C, Nöthen MM, Ossowski S, Pötschke L, Rasokat A, Riess O, Schade S, Schirmacher P, Schmutzler R, Scholl C, Semler SC, Spielmann M, Stegle O, Stenzinger A, Straßburger J, Schröck E, Krawczak M, Kohlbacher O. Germany’s national genomDE strategy. Nat Med. 2025;31(12):3981-3984. doi:10.1038/s41591-025-03991-2
- Skoulidis F, Li BT, de Langen AJ, Hong DS, Lena H, Wolf J, Dy GK, Curioni Fontecedro A, Tomasini P, Velcheti V, van der Wekken AJ, Dooms C, Paz-Ares Rodriguez L, Mountzios G, Sacher A, Nadal E, Couraud S, Kim SW, O’Byrne K, Rocco D, Toyozawa R, Chmielewska I, Lindsay CR, Hindoyan A, Mukundan L, Wilmanski T, Anderson A, Ardito-Abraham C, Pati A, Reddy A, Mehta B, Schuler M. Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer. Nat Med. 2025;31(8):2755-2767. doi:10.1038/s41591-025-03732-5
- Kästner A, Kron A, van den Berg N, Moon K, Scheffler M, Schillinger G, Pelusi N, Hartmann N, Rieke DT, Stephan-Falkenau S, Schuler M, Wermke M, Weichert W, Klauschen F, Haller F, Hummel HD, Sebastian M, Gattenlöhner S, Bokemeyer C, Esposito I, Jakobs F, von Kalle C, Büttner R, Wolf J, Hoffmann W. Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysis. The Lancet Regional Health - Europe. 2024;36:100788. doi:10.1016/j.lanepe.2023.100788
- Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC. Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2024;390(2):118-131. doi:10.1056/NEJMoa2302299
- Wolf J, Hochmair M, Han JY, Reguart N, Souquet PJ, Smit EF, Orlov S v, Vansteenkiste J, Nishio M, de Jonge M, Akerley W, Garon EB, Groen HJM, Tan DSW, Seto T, Frampton GM, Robeva A, Carbini M, le Mouhaer S, Yovine A, Boran A, Bossen C, Yang Y, Ji L, Fairchild L, Heist RS. Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial. Lancet Oncol. 2024;25(10):1357-1370. doi:10.1016/S1470-2045(24)00441-8 Erratum in: Lancet Oncol. 2024;25(11):e542. doi:10.1016/S1470-2045(24)00560-6
- George J, Maas L, Abedpour N, Cartolano M, Kaiser L, Fischer RN, Scheel AH, Weber JP, Hellmich M, Bosco G, Volz C, Mueller C, Dahmen I, John F, Alves CP, Werr L, Panse JP, Kirschner M, Engel-Riedel W, Jürgens J, Stoelben E, Brockmann M, Grau S, Sebastian M, Stratmann JA, Kern J, Hummel HD, Hegedüs B, Schuler M, Plönes T, Aigner C, Elter T, Toepelt K, Ko YD, Kurz S, Grohé C, Serke M, Höpker K, Hagmeyer L, Doerr F, Hekmath K, Strapatsas J, Kambartel KO, Chakupurakal G, Busch A, Bauernfeind FG, Griesinger F, Luers A, Dirks W, Wiewrodt R, Luecke A, Rodermann E, Diel A, Hagen V, Severin K, Ullrich RT, Reinhardt HC, Quaas A, Bogus M, Courts C, Nürnberg P, Becker K, Achter V, Büttner R, Wolf J, Peifer M, Thomas RK. Evolutionary trajectories of small cell lung cancer under therapy. Nature. 2024;627(8005):880-889. doi:10.1038/s41586-024-07177-7
- Kron A, Scheffler M, Wiesweg M, Hummel HD, Kulhavy J, Gatteloehner S, Kollmeier J, Schubart C, Groß T, Demes MC, Keymel S, Joosten M, Merkelbach-Bruse S, Wölwer CB, Tufman A, Kauffmann-Guerrero D, Oeser K, Zehaczek M, Jeratsch U, Wolf J. Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations. Eur J Cancer. 2024;207:114158. doi:10.1016/j.ejca.2024.114158 Erratum in: Eur J Cancer. 2024;213:115074. doi:10.1016/j.ejca.2024.115074
- Zhou C, Solomon B, Loong HH, Park K, Pérol M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, Mak MP, Santini FC, Elamin YY, Drilon A, Wolf J, Payakachat N, Uh MK, Rajakumar D, Han H, Puri T, Soldatenkova V, Lin AB, Lin BK, Goto K. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC. New England Journal of Medicine. 2023;389(20):1839-1850. doi:10.1056/NEJMoa2309457
- Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, Takeda M, Ohe Y, Khan S, Ohashi K, Soldatenkova V, Szymczak S, Sullivan L, Wright J, Drilon A. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022;23(10):1261-1273. doi:10.1016/S1470-2045(22)00541-1
